目的:研究缬沙坦和冬虫夏草制剂联合治疗对2型糖尿病肾病患者的临床疗效。方法:选取2型糖尿病肾病患者150例。按照随机数表法分为缬沙坦组和联合组,每组75例。常规降糖和控制血压治疗,缬沙坦组给予缬沙坦,联合组在给予缬沙坦的基础上给予冬虫夏草制剂。疗程90 d。观察两组患者临床疗效并比较治疗前后患者24 h尿蛋白排泄率(UAER)、血清尿素氮(BUN)、血肌酐(Scr)、血脂、炎症因子水平及血压水平变化。结果:治疗后,两组患者24 h尿蛋白清除率、超敏C-反应蛋白、肿瘤坏死因子-α及血压比较均有显著意义(P<0.05),其他指标治疗后比较无统计学意义;联合组治疗有效率为93.33%,缬沙坦组为69.33%,两组比较具有统计学意义(P<0.05)。结论:缬沙坦和冬虫夏草制剂联合使用明显降低2型糖尿病肾病蛋白尿水平并改善炎症微环境,具有很好的临床疗效,值得在临床推广。 Objective: To study the clinical efficacy of valsartan and Cordyceps combination therapy in patients with type 2 diabetic nephropathy. Methods: 150 cases of type 2 diabetic nephropathy were selected. In accordance with the random number table is divided into valsartan group and combined group, 75 cases in each group. Conventional hypoglycemic and control of blood pressure treatment, valsartan group given valsartan, combination group given valsartan given Cordyceps preparation. Treatment 90 d. The clinical efficacy of the two groups was observed and the 24-hour urinary protein excretion rate (UAER), serum urea nitrogen (BUN), serum creatinine (Scr), blood lipids, inflammatory cytokines and blood pressure levels were compared before and after treatment. Results: After treatment, 24 h urinary protein clearance, Hs-CRP, TNF-α and blood pressure were significantly different between the two groups (P <0.05), and no significant difference was observed after other indexes were treated. The effective rate of combination therapy was 93.33% in the combination group and 69.33% in the valsartan group, with statistical significance (P <0.05). Conclusion: The combined use of valsartan and Cordyceps sinensis significantly reduce proteinuria in type 2 diabetic nephropathy and improve the inflammatory microenvironment, which has good clinical efficacy and is worthy of clinical application.